Structural Heart Devices Market By Product (Heart Valves, Occluders and Delivery Systems, Annuloplasty Rings, Accessories, Others), By Procedure (Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Repair (TMVR), Left Atrial Appendage Closure (LAAC), Surgical Valve Replacement, Others), By Material (Metal, Biological Tissue, Polymer-Based, Others), By End-User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Structural Heart Devices Market in the coming years?

The Structural Heart Devices Market accounted for USD 16.20 Billion in 2024 and USD 18.50 Billion in 2025 is expected to reach USD 69.80 Billion by 2035, growing at a CAGR of around 14.2% between 2025 and 2035. The Structural Heart Devices Market targets a niche of high-technology dental instruments that adopt laser technology to perform multiple dental procedures, providing a more accurate and less invasive alternative to conventional techniques. The devices are applied in surgeries, cavity treatment processes, gum shaping, teeth whitening, and root canal treatment. Lasers are used to minimize pain, bleeding, and recovery time and make dental procedures easier on patients.

Some of the devices in the market are diode lasers, CO2 lasers, and erbium lasers, and each is designed to be used in a specific area of the dentistry profession. The increasing awareness of oral health and the growing preference for painless treatment are fueling adoption. Devices that are easy to carry and use are increasing their application in clinics and hospitals. These tools help provide dental professionals with improved accuracy and shorter procedure times. Increased convergence between lasers and imaging and diagnostic systems is enhancing treatment. The general trend in the market is that modern dentistry is being influenced by efficiency, safety, and the comfort of the patient. 

What do industry experts say about the Structural Heart Devices Market trends?

“The number of heart valve patients being treated has increased with the introduction of transcatheter technologies... surgical volumes have not been impacted as much as people think because more patients overall are now being treated for valve disease.”

• Dr. Samin A. Sharma, MD, a renowned cardiologist specializing in non-surgical valve interventions

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Structural Heart Devices Market?

How is the increasing prevalence of valvular diseases boosting device adoption?

The increasing prevalence of valvular heart diseases is among the key drivers of the structural heart devices market because the disorders often require high-level procedures to restore normal heart function. Examples of valvular disorders that are very serious and have dire consequences when not addressed are aortic stenosis and mitral regurgitation. Both transcatheter and surgical valves are structural heart devices that provide effective therapy with good patient outcomes and survival rates. As the aging community increasingly falls victim to these diseases, there is consequently an increasing demand to develop new heart valves.

To combat such challenges, healthcare providers are increasingly resorting to the use of minimally invasive techniques such as TAVR due to their safety and ease of recovery. The U.S. Centers for Disease Control and Prevention (CDC) estimates that valvular heart disease occurs in approximately 2.5 percent of the American population, and the prevalence rate of this disease increases rapidly with age, particularly in people over 65 years of age. The increasing disease burden is evidence of the necessity of durable and reliable devices. With better awareness and increased diagnostic capabilities, the use of structural heart devices will only grow faster to become an important solution in cardiology today.

Why is global demand for minimally invasive TAVR and TMVR growing?

Transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) are two minimally invasive procedures whose use is increasingly in demand around the world, making them highly compelling drivers of the structural heart devices market. Compared to open-heart surgery, these techniques include smaller cuts, shorter hospitalization, and a quicker recovery, which is hugely beneficial to older patients and those at high risk. Reduced chances of complications and better prognosis in the long run have prompted medical practitioners to use these methods on a larger scale. With the dissemination of awareness, patients are now favoring minimally invasive procedures that are safe and comfortable.

The high levels of success in procedures are also being supported by continuing improvements in device design and imaging guidance that are making the procedures more popular. The National Institutes of Health (NIH) reports that there has been a considerable increase in the use of TAVR, as high-risk patients have been replaced with intermediate and even lower-risk patients. This trend indicates solid clinical evidence of the safety and effectiveness of minimally invasive valve therapies. As the world population ages and the burden of disorders associated with the valves increases, TAVR and TMVR will likely continue to occupy the spotlight of structural heart devices market development.

How does the high cost of devices limit patient affordability worldwide?

The expensive nature of structural heart devices is also a major constraining factor in the structural heart devices market, since it directly affects patient accessibility across the globe. To implement procedures like TAVR or TMVR, there are technologies and special equipment involved, which are much more costly than traditional surgical techniques. The absence of comprehensive reimbursement policies in most regions also contributes to the high financial cost of patients receiving such life-saving treatments. This disincentive is more acute in developing economies, where the amount of money spent on health services per capita is comparatively low, and out-of-pocket costs are large.

In developed markets, these advanced interventions are only easily accessible to patients with good insurance coverage or government support. The treatment is expensive, as the device itself, hospital costs, special treatment, and follow-up treatment are not the only expenses. Consequently, even with established clinical advantages of structural heart devices, they have not been widely used, especially by lower- and middle-income groups. This low-cost barrier still impedes fair access to the latest cardiac care solutions, slowing down the general market growth.

How can TAVR and TMVR expand into lower-risk patient populations?

The inclusion of transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) in the lower-risk patient groups represents one of the biggest opportunities for the Structural Heart Devices market. Typically, only used on high-risk patients who could not receive open-heart surgery, these procedures have now proven to be both safe and effective in wider populations. It has been demonstrated in clinical trials and real-world evidence that minimally invasive valve therapies could result in equivalent or even better outcomes than surgical therapies, so they should be used in patients with intermediate and low risk. This broad accessibility significantly increases the number of patients that manufacturers and healthcare providers can address with their devices.

Younger and more active lower-risk patients are more prone to interventions that provide faster recovery, fewer complications, and longevity. The usage rates will increase steadily as regulatory entities approve broader indications and doctors develop further expertise. Being able to treat a significantly greater number of patients with minimally invasive solutions not only causes the market to grow, but also preconditions the ever-present development of device design and delivery systems. Such a trend makes TAVR and TMVR key growth drivers, which are opening new opportunities in the Structural Heart Devices Market.

Why do growing healthcare investments in developing nations drive market growth?

The Structural Heart Devices Market has a big opportunity in growing healthcare investments in developing countries, which can immediately increase access to hi-tech cardiac services. Lots of developing countries are increasing the number of healthcare facilities, developing specialized cardiac centers, renovating hospitals, and establishing modern diagnostic centers. These advancements allow expanded access to previously restricted to the developed world procedures, like TAVR, TMVR, and LAAC. Advanced treatments are also becoming more affordable and available to more people due to increased government funding and the involvement of private companies in the treatment process.

With the modernization of healthcare systems, the knowledge of structural heart conditions and treatment options is increasing among patients and providers. Training and joint work with world experts also increase the level of local competence, which guarantees the effective implementation of these innovative processes. Moreover, budget increases in developing countries enable faster implementation of innovative devices, which address gaps in treatment. This increased coverage and uptake in previously underserved markets is creating new growth opportunities, making healthcare investment in emerging markets one of the primary sources of opportunity in the Structural Heart Devices Market.

What are the key market segments in the Structural Heart Devices industry?

Based on the Product Type, the Structural Heart Devices Market has been classified into Robotic Surgical Systems, Heart Valves, Occluders and Delivery Systems, Annuloplasty Rings, and Accessories. Heart Valves are the leading category of the structural heart devices market, mainly because of the prevalence of valvular heart diseases and the rising popularity of minimally invasive valve replacement surgeries. Heart valves are very important in controlling blood flow, and when they are defective then they may need to be repaired in a surgical or transcatheter manner. Transcatheter aortic valve replacement (TAVR) is one of the most widely used procedures because its introduction has transformed the treatment of at-risk patients with at least a high or moderate surgical risk.

Other advances in valve design, including enhanced durability, superior hemodynamic performance, and minimizing the danger of complications, have also contributed to the dominance of this segment. Moreover, the increasing population of the world today has led to an increase in cases of aortic stenosis and mitral regurgitation, which directly drives the demand for heart valves. To increase access to treatment and enhance patient outcomes, hospitals and heart centers are investing in new and more sophisticated valve technologies. In addition, the segment has the advantage of continuous clinical trials and regulatory approvals, which provide a stable source of next-generation devices. Having its principal position in the treatment of life-threatening cardiac diseases, the heart valves segment is the largest and the most influential in the structural heart devices market.

Based on the Procedure, the Structural Heart Devices Market has been classified into Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Repair (TMVR), Left Atrial Appendage Closure (LAAC), Surgical Valve Replacement, and Others. Transcatheter Aortic Valve Replacement (TAVR) is the largest segment in the structural heart devices market because of its revolutionary effects in the management of aortic stenosis. The TAVR has established itself as the modality of choice among patients with either high or intermediate surgical risk because it provides patients with a less invasive option to the conventional open-heart procedure. It has the benefit of significantly reducing recovery time, reducing risks of complications, and improving overall patient outcomes, and this has led to its rapid adoption in many countries across the globe. Ongoing improvements in valve design and delivery have increased the range of patients who can receive TAVR, including those who are less surgically risky.

It is also dominating because of the growing knowledge of physicians, the growing access to specialized cardiac centers, and the expanding range of indications that are allowed by regulating authorities. Investment in TAVR programs by hospitals is also a priority in addressing the increased demand for less invasive interventions. Additionally, the use of TAVR has been extensively shown to be effective and safe in the long term; this fact is precisely why healthcare professionals are increasingly confident. Having proven its success and being able to treat a critical, extensive condition, TAVR is undoubtedly the most dominant procedure segment in the structural heart devices market.

Which regions are leading the Structural Heart Devices Market, and why?

The North America Structural Heart Devices Market is also experiencing a stable growth, as more advanced dental technologies are becoming more widespread and more emphasis is placed on patient-centered treatment. Laser equipment is being used more and more in dental clinics and hospitals, providing increasingly accurate, minimally invasive services.

The area has the advantage of a well-developed health care system and an increasing pool of trained medical and dental practitioners familiar with the use of lasers. There is an increasing acceptance amongst dental practitioners due to technological advances and constant product innovations. The increasing awareness of oral health and preference for painless treatment is further driving growth in the market. Training and use are being encouraged through collaboration between manufacturers of dental devices and dental institutions. There is also a trend in the market towards portable and multi-purpose laser systems that enhance functionality. By and large, North America continues to be one of the major centers of innovation and uptake in laser dentistry.

The Asia Pacific Structural Heart Devices Market is developing fast due to the increasing knowledge of patients about advanced dental care. Urban adoption is being stimulated by a growing availability of disposable income and by a growing demand to undergo dental operations in a more modern and painless way. Investment in dental infrastructure is being realized in countries in the region through the establishment of clinics with the latest laser technologies.

Laser machines are slowly being used by dental specialists in surgeries, gum therapy, and cosmetic surgeries because of their accuracy and effectiveness. Easier deployment is being aided by technological advances such as small and easy-to-use laser systems. Practitioners are being trained to acquire skills in the use of lasers through training programs and workshops. The market is also growing due to the demand for cosmetic and preventive dental treatments. On the whole, the region is becoming a big market that can grow even further.  

What does the competitive landscape of the Structural Heart Devices Market look like?

The Structural Heart Devices Market can be described as the competitive environment that may include both the global leaders in the field and the innovators that have yet to make their appearance in the regional market. The market is dominated by leading firms like Dentsply Sirona, BIOLASE, Fotona, Convergent Dental, and AMD Lasers, which have a wide variety of laser systems depending on the type of dental application required. These industrial giants are known to have been technologically advanced, had an extensive product range, and brand presence in various geographic areas. Besides these giant players, other firms also play a role in the dynamics of the market.

Notable examples of innovative product delivery and specialized offerings in the field of dental laser technologies are Sirona Dental Systems, KaVo Kerr, DenMat Holdings, and Ultradent Products. Their emphasis on improving the treatment accuracy and patient comfort has made them major competitors in the international market. Regional competition can also be influenced by players such as Gigaalaser, LaserSmile, and Yoshida Dental MFG. Co., and A.R.C. Laser that serve local demands and preferences.

Structural Heart Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Structural Heart Devices industry?

• In April 2025, UPMC’s Heart and Vascular Institute in Central Pennsylvania became the first in the state to perform a valve-in-valve TAVR procedure using a newly FDA-approved leaflet modification device aimed at reducing the risk of coronary obstruction in high-risk patients.
• In April 2025, LUMA Vision received FDA clearance for its VERAFEYE platform, which provides real-time 360° catheter navigation support for structural heart and electrophysiology procedures.
• In November 2024, Pi-Cardia obtained De Novo authorization from the U.S. Food and Drug Administration (FDA) for its Shortcut system, an innovative device developed to assist valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures by tackling the challenge of coronary obstruction.

Report Coverage:

By Product Type

• Heart Valves
• Occluders and Delivery Systems
• Annuloplasty Rings
• Accessories
• Others

By Procedure

• Transcatheter Aortic Valve Replacement (TAVR)
• Transcatheter Mitral Valve Repair (TMVR)
• Left Atrial Appendage Closure (LAAC)
• Surgical Valve Replacement
• Others

By Material

• Metal
• Biological Tissue
• Polymer-Based
• Others

By End-User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• Abbott Laboratories
• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• CryoLife, Inc.
• Lepu Medical Technology Co., Ltd.
• MicroPort Scientific Corporation
• JenaValve Technology, Inc.
• Braile Biomédica
• Meril Life Sciences Pvt. Ltd.
• Comed B.V.
• Peijia Medical Limited
• Venus Medtech (Hangzhou) Inc.
• CardioKinetix, Inc.
• Xeltis AG

Frequently Asked Questions (FAQs)